Derosa Giuseppe, Cicero Arrigo F G, D'Angelo Angela, Borghi Claudio, Maffioli Pamela
Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, PAVIA, Italy.
Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical Research, University of Pavia, PAVIA, Italy.
Biofactors. 2016 May;42(3):316-22. doi: 10.1002/biof.1277. Epub 2016 Apr 4.
to evaluate if a supplementation with n-3 PUFAs at high doses could give a regression of the condition of impaired glycemia.
we enrolled 281 overweight/obese patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT); 138 subjects were randomized to n-3 PUFAs group, 1 g three times a day, and 143 to placebo for 18 months. We assessed at baseline, and after 9, and 18 months: circumferences, body mass index (BMI), fasting plasma glucose (FPG), fasting plasma insulin (FPI), HOMA-index, lipid profile. At baseline and at the end of the study, all patients underwent an oral glucose tolerance test (OGTT).
we observed a decrease of glycemia and HOMA-IR with n-3 PUFAs, compared to baseline, and to placebo. Fasting plasma insulin decreased with n-3 PUFAs and increased with placebo. HDL-cholesterol increased after 18 months of n-3 PUFAs, while triglycerides decreased compared to baseline and to placebo. After OGTT performed at the end of the study, more patients returned to a condition of euglycemia with n-3 PUFAs compared to placebo.
n-3 PUFAs were effective in reducing glycemia in patients affected by IFG or IGT and seem to be helpful to slow the development of type 2 diabetes mellitus. © 2016 BioFactors, 42(3):316-322, 2016.
评估高剂量补充n-3多不饱和脂肪酸（PUFAs）是否能使血糖受损状况得到改善。
我们招募了281名空腹血糖受损（IFG）或糖耐量受损（IGT）的超重/肥胖患者；138名受试者被随机分为n-3 PUFAs组，每天3次，每次1克，143名受试者被分为安慰剂组，为期18个月。我们在基线时、9个月后和18个月后评估：腰围、体重指数（BMI）、空腹血糖（FPG）、空腹血浆胰岛素（FPI）、稳态模型评估胰岛素抵抗指数（HOMA-index）、血脂谱。在基线和研究结束时，所有患者均接受口服葡萄糖耐量试验（OGTT）。
与基线和安慰剂相比，我们观察到n-3 PUFAs组的血糖和HOMA-IR有所下降。n-3 PUFAs组的空腹血浆胰岛素下降，而安慰剂组上升。n-3 PUFAs组治疗18个月后高密度脂蛋白胆固醇升高，而甘油三酯与基线和安慰剂相比均下降。在研究结束时进行OGTT后，与安慰剂相比，n-3 PUFAs组有更多患者恢复到血糖正常状态。
n-3 PUFAs对降低IFG或IGT患者的血糖有效，似乎有助于减缓2型糖尿病的发展。©2016生物因子，42(3):316 - 322，2016。
